Literature DB >> 7986334

Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults.

A R Hayward1, K Buda, M J Levin.   

Abstract

Healthy varicella zoster virus (VZV) immune subjects > 55 years old, were immunized with 4,000 PFU of Oka strain VZV live vaccine or a similar amount of heat-inactivated vaccine. A subset of each group was also immunized with tetanus toxoid (TT) 3 months before receiving the VZV vaccine. The live and inactivated VZV vaccine groups had similar ages, sex distribution, and previous immunity to VZV. The live and inactivated VZV vaccines elicited similar increases in the frequency in blood of VZV-specific T cells, in vitro interferon-gamma production, and serum antibody levels both 3 and 12 months after immunization. Individuals with the highest responder cell frequency (RCF) at entry had the highest postimmunization RCF following either vaccine. There was no correlation at entry between the RCF to TT or RCF to VZV. There was a weak (P = 0.05) correlation in the incremental response to TT and VZV among individuals who responded to both vaccines. Entry variables that did not correlate with the response included percent of T cells or the CD45R0 (memory) T cell subset in blood, serum antibody levels, or amount of interferon-gamma production. The results indicate that the inactivated vaccine is safe for VZV-immune subjects and boosts their antibody and T-cell responses as effectively as the live vaccine for at least 1 year following immunization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986334     DOI: 10.1089/vim.1994.7.31

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  10 in total

Review 1.  KLRG1--more than a marker for T cell senescence.

Authors:  Sian M Henson; Arne N Akbar
Journal:  Age (Dordr)       Date:  2009-12

Review 2.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

Review 3.  Vaccination in the elderly: what can be recommended?

Authors:  Pierre-Olivier Lang; Richard Aspinall
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

4.  KLRG1 impairs CD4+ T cell responses via p16ink4a and p27kip1 pathways: role in hepatitis B vaccine failure in individuals with hepatitis C virus infection.

Authors:  Lei Shi; Jia M Wang; Jun P Ren; Yong Q Cheng; Ruo S Ying; Xiao Y Wu; Shu M Lin; Jeddidiah W D Griffin; Guang Y Li; Jonathan P Moorman; Zhi Q Yao
Journal:  J Immunol       Date:  2013-12-13       Impact factor: 5.422

5.  Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus.

Authors:  J G Smith; X Liu; R M Kaufhold; J Clair; M J Caulfield
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

Review 6.  Strategies for herpes zoster vaccination of immunocompromised patients.

Authors:  Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

Review 7.  Vaccines for preventing herpes zoster in older adults.

Authors:  Anna M Z Gagliardi; Brenda N G Andriolo; Maria R Torloni; Bernardo G O Soares
Journal:  Cochrane Database Syst Rev       Date:  2016-03-03

8.  Reversal of functional defects in highly differentiated young and old CD8 T cells by PDL blockade.

Authors:  Sian M Henson; Richard Macaulay; Ornella Franzese; Arne N Akbar
Journal:  Immunology       Date:  2012-04       Impact factor: 7.397

9.  Vaccines for preventing herpes zoster in older adults.

Authors:  Anna Mz Gagliardi; Brenda Ng Andriolo; Maria Regina Torloni; Bernardo Go Soares; Juliana de Oliveira Gomes; Regis B Andriolo; Eduardo Canteiro Cruz
Journal:  Cochrane Database Syst Rev       Date:  2019-11-07

Review 10.  Effect of Routine Varicella Immunization on the Epidemiology and Immunogenicity of Varicella and Shingles.

Authors:  Naruhito Otani; Masayuki Shima; Takuma Yamamoto; Toshiomi Okuno
Journal:  Viruses       Date:  2022-03-12       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.